Your session is about to expire
← Back to Search
Combination Drug Therapy for Obstructive Sleep Apnea (RESCUE-Combo Trial)
RESCUE-Combo Trial Summary
This trial will test a combination of three drugs to see if they're more effective in treating obstructive sleep apnea than single-drug therapies.
- Obstructive Sleep Apnea
RESCUE-Combo Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RESCUE-Combo Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have moderate or severe untreated sleep apnea with specific measurements showing how often you stop breathing during sleep.You have a disorder that affects your body's natural sleep-wake cycle.You have long-term liver disease or kidney disease in its final stage.You have a psychiatric disease, except for well-controlled depression or anxiety.You are consistently using a treatment that effectively manages obstructive sleep apnea.You have any untreated sleep disorder that causes frequent disruptions in your sleep, like periodic limb movement disorder or narcolepsy.You have a tracheostomy.You had stomach surgery to help with weight loss.You regularly take certain medications that can affect your breathing control.Your body mass index (BMI) is between 18 and 40.You cannot take the study drugs if you are allergic to any of them, have certain medications in your system, or have severe nighttime breathing problems.You have not had surgery to improve blood flow to your heart, or you have a history of chest pain, heart attack, stroke, or heart failure.Your blood pressure is very high and not controlled with medication.You are taking certain medications that have similar effects to the study drug.You can't sleep on your back for overnight sleep tests.You had stomach or intestinal bleeding or ulcers in the past 5 years.You currently use illegal drugs or drink more than 2 drinks of alcohol per day.
- Group 1: Placebo, then Dual-Therapy, then Single/Triple-Therapy
- Group 2: Dual-Therapy, then Placebo, then Single/Triple-Therapy
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Am I eligible to be a part of this medical experiment?
"To participate in this trial, patients should have a confirmed case of sleep apnea and must be between 18-65 years old. This clinical study is limited to 20 participants in total."
What therapeutic purposes does Venlafaxine typically serve?
"Venlafaxine is a common pharmaceutical for sleep-related issues. Additionally, it can be helpful in treating breast cancer, hormonal shifts during menopause, and metabolic alkalosis."
What is the current population sample size of this trial?
"Affirmative. The clinical trial, first posted on January 1st 2020 and recently updated in September 2021 according to data hosted by clinicaltrials.gov, is actively searching for recruits. Only 20 participants are needed from 2 medical centres."
Has Venlafaxine previously been assessed through clinical experimentation?
"Currently, there are 27 active trials for Venlafaxine with 9 of those being in Phase 3. Salt Lake City, Utah is the main hub for these studies; however, 78 other medical centres across the nation have begun research related to this drug as well."
Are there any vacancies for involvement in this research study?
"Affirmative. As evidenced by records documented on clinicaltrials.gov, this research is recruiting participants at present. This study was first published on the 1st of January 2020 and has been amended as recently as September 22nd 2021, with a target recruitment count of 20 individuals from 2 respective locations."
Does the use of Venlafaxine present any potential safety risks?
"With Phase 2 clinical trials providing evidence of safety, but no data yet on efficacy, our analysts at Power estimated the security of venlafaxine to be a score of 2."
Is the minimum age requirement for this investigation below sixty years?
"This research project is open to individuals aged 18 or older and below the age of 65."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger